Monika Eichinger
Overview
Explore the profile of Monika Eichinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ringwald F, Wucherpfennig L, Hagen N, Mucke J, Kaletta S, Eichinger M, et al.
Front Med (Lausanne)
. 2024 Nov;
11:1401473.
PMID: 39606627
Introduction: Segmentation of lung structures in medical imaging is crucial for the application of automated post-processing steps on lung diseases like cystic fibrosis (CF). Recently, machine learning methods, particularly neural...
2.
Ringshausen F, Baumann I, de Roux A, Dettmer S, Diel R, Eichinger M, et al.
Pneumologie
. 2024 Nov;
78(11):833-899.
PMID: 39515342
Bronchiectasis is an etiologically heterogeneous, chronic, and often progressive respiratory disease characterized by irreversible bronchial dilation. It is frequently associated with significant symptom burden, multiple complications, and reduced quality of...
3.
Grott M, Khan N, Eichhorn M, Heussel C, Winter H, Eichinger M
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335134
Contrast-enhanced computed tomography (CT) is the standard radiologic examination for evaluating the extent of mediastinal tumors. If tumor infiltration into the large central thoracic vessels, the pericardium, or the myocardium...
4.
Wielputz M, Stahl M, Triphan S, Wucherpfennig L, Leutz-Schmidt P, Gestewitz S, et al.
Ann Am Thorac Soc
. 2024 Sep;
PMID: 39255452
Rationale: The progression of lung changes in cystic fibrosis (CF) from infancy through adolescence remains poorly understood due to limited longitudinal imaging data. Objectives: To assess changes in lung morphology...
5.
Stahl M, Roehmel J, Eichinger M, Doellinger F, Naehrlich L, Kopp M, et al.
Ann Am Thorac Soc
. 2024 Aug;
21(11):1550-1559.
PMID: 39173175
Clinical trials show that lumacaftor/ivacaftor (LUM/IVA) treatment has the potential to modify early cystic fibrosis (CF) disease progression in children as young as 2 years of age. To assess the...
6.
Trudzinski F, Athanasiou C, Eberhardt R, Michels-Zetsche J, Schellenberg M, Eichinger M, et al.
Respir Med
. 2024 Aug;
233:107772.
PMID: 39142597
Background: To date there are no data on sex aspects evaluating outcomes of interventional pneumology (IP). Our aim was to investigate sex differences in transbronchial lung cryobiopsy (TBLC) outcomes in...
7.
Niedermaier B, Kou Y, Tong E, Eichinger M, Klotz L, Eichhorn M, et al.
Lung Cancer
. 2024 Jul;
194:107890.
PMID: 39003936
Introduction: Histological confirmation of a lung tumor is the prerequisite for treatment planning. It has been suspected that CT-guided needle biopsy (CTGNB) exposes the patient to a higher risk of...
8.
Guttlein M, Wucherpfennig L, Kauczor H, Eichinger M, Heussel C, Wielputz M
Radiologie (Heidelb)
. 2024 Jun;
64(8):617-627.
PMID: 38937303
Background: Cystic and nodular lung diseases encompass a broad spectrum of diseases with different etiologies and clinicoradiological presentations. Their differentiation is crucial for patient management but can be complex due...
9.
Triphan S, Konietzke M, Biederer J, Eichinger M, Vogelmeier C, Jorres R, et al.
Front Med (Lausanne)
. 2024 Jan;
10:1254003.
PMID: 38249975
Introduction: Due to hypoxic vasoconstriction, perfusion is interesting in the lungs. Magnetic Resonance Imaging (MRI) perfusion imaging based on Dynamic Contrast Enhancement (DCE) has been demonstrated in patients with Chronic...
10.
Wucherpfennig L, Becker J, Wuennemann F, Eichinger M, Seitz A, Baumann I, et al.
J Cyst Fibros
. 2024 Jan;
23(2):234-241.
PMID: 38218661
Introduction: Previous studies using magnetic resonance imaging (MRI) demonstrated early onset and progression of chronic rhinosinusitis (CRS) from infancy to school age, and response to lumacaftor/ivacaftor (LUM/IVA) therapy in children...